# Biomatics Capital Partners

> Biomatics Capital Partners is a VC fund backing Biotechnology and Health Care. See 27 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Seattle, United States
- Total investments: 27
- Last investment: Jan 2021
- Lead investor: 19%
- Fund size: $300M
- Last fund: Nov 2018
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/biomatics-capital/
- Website: https://www.biomaticscapital.com/

Biomatics Capital Partners is a Seattle-based healthcare and life sciences venture firm. Biomatics is a $200 million fund that focuses on early-stage investments, primarily in genomics and digital health. Co-founders and General Partners Dr. Boris Nikolic and Julie Sunderland have invested together in emerging technology, health care, and lifescience ventures since 2010, leveraging their deep technical knowledge and partnering expertise with an established network of leading academics, pharma executives and venture capital firms.

## Contacts

5 contacts available for Biomatics Capital Partners. Shizune tracks 2 team members at Biomatics Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/biomatics-capital-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 48% |
| Health Care | 8 | 30% |
| Medical | 7 | 26% |
| Biopharma | 3 | 11% |
| Life Science | 3 | 11% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 10 | 37% |
| Series B | 9 | 33% |
| Series C | 5 | 19% |
| Funding Round | 1 | 4% |
| Venture - Series Unknown | 1 | 4% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 15 | 56% |
| China | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Julie Sunderland | Managing Director | 2 | — |
| Boris Nikolic | Co-Founder & Managing Director | 4 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Encodia | Encodia provides in-depth information on cellular processes to enable personalized medicine.Our technology reverse translates peptide sequence information into a DNA library. This means scientists can scale their research more easily to accelerate novel approaches to our most challenging diseases.Encodia was established on January 1, 2015 inSan Diego, California. | $75M | Series C | Jan 27, 2021 |  |
| Verve Therapeutics | Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids suchas low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. | $94M | Series B | Jan 19, 2021 |  |
| Thrive Earlier Detection | Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering.The company waslaunched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3. | $257M | Series B | Jul 29, 2020 |  |
| Compass Therapeutics | Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeuticsthat can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. | $60.5M | Venture - Series Unknown | Jun 23, 2020 |  |
| Verve Therapeutics | Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids suchas low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. | $63M | Series A | Jun 11, 2020 |  |
| Omniome | Omniome engages in developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome’s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing.Founded in 2013, the company isheadquartered in San Diego, California, United States. | $60M | Series C | Jan 09, 2020 |  |
| AiCure | AiCure is an advanced data analytics company that uses artificial intelligence to understand how patients respond to treatments. It enables intelligent decision-making and improving health outcomes. It has developed patented facial recognition and motion-sensing technology to confirm medication ingestion in real-time.AiCure's platform hasthe potential to revolutionize the cost-effectiveness of healthcare delivery systems by enhancing treatment and reducing risks. Their software captures and understands video, audio, and behavioral data to establish the link between patients, disease, and treatment.It was founded in 2010 and is headquartered in New York. | $24.5M | Series C | Nov 07, 2019 |  |
| EGenesis | EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide. | $100M | Series B | Nov 07, 2019 |  |
| BlackThorn Therapeutics | BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historicchallenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment. | $76M | Series B | Jun 13, 2019 |  |
| Thrive Earlier Detection | Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering.The company waslaunched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3. | $110M | Series A | May 30, 2019 |  |

10 of 27 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 12 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 11 deals together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 5 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 4 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 4 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Biomatics Capital Partners invest in?

Biomatics Capital Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Biomatics Capital Partners?

Public channels for Biomatics Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Biomatics Capital Partners?

The team at Biomatics Capital Partners includes Julie Sunderland (Managing Director) and Boris Nikolic (Co-Founder & Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co